Phathom Pharmaceuticals Inc (PHAT) Stock Price, Quote & News

Company Profile

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heart...

Industry: Biotechnology

Sector: Healthcare

Phone: 877 742 8466

Website: www.phathompharma.com

Address:

100 Campus Drive, Suite 102, Florham Park, United States

Lolichocho Feb. 23 at 7:45 PM

$PHAT added these low 11s this week and last. My attention has been elsewhere lately, can someone lmk real quick how scripts have been looking? Any slowdown in growth? I scrolled a bit but don't see any posted lately. Ty very much

1 · Reply

fgggggggg Feb. 23 at 7:06 PM

$PHAT

0 · Reply

Joe_90_ Feb. 21 at 7:52 PM

$PHAT Management to host conference call on Thursday, February 26, 2026, at 8:00 am EST FLORHAM PARK, N.J., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EST on Thursday, February 26, 2026, to report its fourth quarter and full year 2025 financial results and provide a business update. live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations.

0 · Reply

UgoGreg Feb. 21 at 5:12 PM

$PHAT https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 21 at 12:10 PM

$PHAT RSI: 27.63, MACD: -0.7821 Vol: 0.85, MA20: 12.93, MA50: 14.59 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Morrito23 Feb. 20 at 10:43 PM

$PHAT nothing has changed except the news about dilution. No more can be said to explain what’s happening to the price. Maybe macro conditions. If short don’t use this opportunities to cover, I’d be surprised. If I remember correctly these were about the prices when we started seeing our short numbers really increase. I wouldn’t be surprised if this went lower so that they can lock in some type of profit form covering. That and all the 12.5 calls expired worthless today. Option plays are pretty much nonexistent for us now.

2 · Reply

GSTX7 Feb. 20 at 8:38 PM

$PHAT 11.29 - Just dropped a big add.

0 · Reply

Randy_Lahey_Trevor_Corey Feb. 20 at 8:36 PM

$PHAT honestly someone make it make sense lmao

1 · Reply

longshot45 Feb. 20 at 8:19 PM

$PHAT Just picked up another 325. Thanks for the discount!

0 · Reply

StardustTrader Feb. 20 at 6:45 PM

$PHAT were at a massive inflection point. Currently on the daily 200day sma with the weekly 50 crossing over the 200 (currently just above 10 dollars) and the monthly 20sma crossing over the 50. Shorts have nothing but technicals to drive on. Perfect spot to buy here. And i am adding.

2 · Reply

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

Feb 17, 2026, 8:00 AM EST - 6 days ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on Thursday, February 26, 2026

Feb 5, 2026, 8:00 AM EST - 18 days ago

Phathom Pharmaceuticals to Present at the Guggenheim Emerging Outlook Biotech Summit 2026

Jan 7, 2026, 10:33 PM EST - 6 weeks ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:05 PM EST - 6 weeks ago

Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 7, 2026, 4:01 PM EST - 6 weeks ago

Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results

Nov 21, 2025, 4:03 PM EST - 3 months ago

Phathom Pharmaceuticals: Superior Efficacy Drives Vonoprazan Growth

Nov 4, 2025, 8:00 AM EST - 3 months ago

Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Oct 30, 2025, 1:26 PM EDT - 4 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

Oct 30, 2025, 7:00 AM EDT - 4 months ago

Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 25, 2025, 9:59 AM EDT - 4 months ago

Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting

Oct 20, 2025, 8:00 AM EDT - 4 months ago

Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025

Oct 6, 2025, 1:29 PM EDT - 5 months ago

My Top 5 Biotech Stocks Big Pharma Could Buy Next

ABBV ALVO AMGN ARKG AZN BIIB BMY

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer

Aug 20, 2025, 8:00 AM EDT - 6 months ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D Filing

Aug 7, 2025, 10:51 PM EDT - 7 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 6:59 AM EDT - 7 months ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 28, 2025, 8:00 AM EDT - 7 months ago

Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025

Jun 25, 2025, 4:54 AM EDT - 8 months ago

Phathom Pharmaceuticals: Potential Blockbuster Gastric Acid-Reducing Drug With New Mechanism

Jun 23, 2025, 4:15 PM EDT - 8 months ago

Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 23, 2025, 7:59 AM EDT - 8 months ago

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

SAGE

Jun 16, 2025, 8:00 AM EDT - 9 months ago

Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032

Jun 10, 2025, 10:08 AM EDT - 9 months ago

Tiny Phathom Pharmaceuticals Just An Got FDA Blessing And Big-Time Upside: Buy

Jun 6, 2025, 12:27 PM EDT - 9 months ago

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

May 1, 2025, 12:09 PM EDT - 10 months ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2025 Earnings Call Transcript

May 1, 2025, 7:00 AM EDT - 10 months ago

Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

ITCI

Apr 28, 2025, 7:59 AM EDT - 10 months ago

Phathom Pharmaceuticals to Present VOQUEZNA® (vonoprazan) Data at DDW 2025 Annual Meeting

Apr 23, 2025, 8:00 AM EDT - 10 months ago

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

Apr 17, 2025, 8:00 AM EDT - 11 months ago

Frazier Life Sciences Appoints Aditya Kohli to Partner

HLVX

Apr 16, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Appoints Ted Schroeder to its Board of Directors

CDTX

Apr 3, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 11 months ago

Phathom Pharmaceuticals Announces Leadership Succession

Mar 31, 2025, 7:59 AM EDT - 11 months ago

Actor and Comedian Kenan Thompson Teams Up with Phathom Pharmaceuticals to Raise Awareness About GERD and VOQUEZNA® (vonoprazan)

Mar 6, 2025, 12:13 PM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 24, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

Jan 29, 2025, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals to Present at the Guggenheim Securities SMID Cap Biotech Conference

Dec 11, 2024, 8:00 AM EST - 1 year ago

Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets

Nov 10, 2024, 3:54 AM EST - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024

Oct 27, 2024, 12:00 PM EDT - 1 year ago

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants

Aug 10, 2024, 2:52 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Jul 18, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Relief of Heartburn Associated with Non-Erosive GERD in Adults

Jun 26, 2024, 6:11 AM EDT - 1 year ago

Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays

May 11, 2024, 7:03 PM EDT - 1 year ago

Phathom Pharmaceuticals, Inc. (PHAT) Q1 2024 Earnings Call Transcript

May 9, 2024, 8:00 AM EDT - 1 year ago

Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Lolichocho Feb. 23 at 7:45 PM

1 · Reply

fgggggggg Feb. 23 at 7:06 PM

$PHAT

0 · Reply

Joe_90_ Feb. 21 at 7:52 PM

0 · Reply

UgoGreg Feb. 21 at 5:12 PM

$PHAT https://youtu.be/ygBN8MilTyc

0 · Reply

OfficialStocktwitsUser Feb. 21 at 12:10 PM

0 · Reply

Morrito23 Feb. 20 at 10:43 PM

2 · Reply

GSTX7 Feb. 20 at 8:38 PM

$PHAT 11.29 - Just dropped a big add.

0 · Reply

Randy_Lahey_Trevor_Corey Feb. 20 at 8:36 PM

$PHAT honestly someone make it make sense lmao

1 · Reply

longshot45 Feb. 20 at 8:19 PM

$PHAT Just picked up another 325. Thanks for the discount!

0 · Reply

StardustTrader Feb. 20 at 6:45 PM

2 · Reply

Quantumup Feb. 20 at 12:41 PM

Raymond James resumed coverage on $EPRX and said, We are resuming coverage of Eupraxia Pharmaceuticals (EPRX) with a Strong Buy rating and $18 target price. $SNY - REGN $TAK $BMY AZN PFE $PHAT Raymond James added, The company's DiffuSphere platform enables the encapsulation of virtually any small molecule, creating drug-infused nanoparticles with greatly extended dosing intervals (~12 months) and localized tissue deposition. Their lead asset is EP-104GI, a DiffuSphere formulation of fluticasone being developed for the treatment of eosinophilic esophagitis (EoE). We see EP-104GI possessing best-in-class potential as a steroid treatment in PPI-refractory EoE patients, with topline data from Part B of the ongoing placebo-controlled Phase 2 RESOLVE study expected in 2H26.

0 · Reply

Ecryder Feb. 19 at 9:07 PM

$PHAT wow great end of the day….but did we hit the bottom?

0 · Reply

JP2024 Feb. 19 at 3:36 PM

$PHAT ugh

0 · Reply

StardustTrader Feb. 18 at 9:30 PM

$PHAT follow the channels..

0 · Reply

longshot45 Feb. 18 at 9:21 PM

$PHAT Huge options action today for this Friday’s options. Looking forward to what happens once this logjam clears

0 · Reply

Randy_Lahey_Trevor_Corey Feb. 18 at 6:49 PM

$PHAT joke

0 · Reply

Walleyeslayer Feb. 18 at 4:56 PM

$PHAT back before the big run up they cut this from 4 down to 2 in a week and then ran it to 12 in one day. I’ll hold now and add on a large dip. I’m betting it’ll pay off eventually.

0 · Reply

Walleyeslayer Feb. 18 at 4:54 PM

$PHAT volume 200k. Easily manipulated.

0 · Reply

Morrito23 Feb. 18 at 4:31 PM

$PHAT My neck is about to break from this whiplash.

1 · Reply

Randy_Lahey_Trevor_Corey Feb. 18 at 4:12 PM

$PHAT makes sense

0 · Reply

Canvasback33 Feb. 18 at 3:45 PM

$PHAT what was that sell off?

0 · Reply

fgggggggg Feb. 18 at 1:59 AM

$PHAT earnings are a full week ahead of last year. February 26th at 8am

1 · Reply

Market Cap	815.62M
Revenue (ttm)	55.25M
Net Income (ttm)	-334.33M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-605.12%
Debt to Equity Ratio	-0.49

Volume	1,089,400
Avg Vol	1,108,734
Day's Range	N/A - N/A
Shares Out	71.42M
Stochastic %K	17%
Beta	0.51
Analysts	Strong Sell
Price Target	$22.90